CytoDyn Inc. SEC filings CYDY
CytoDyn Inc. has 1,001 filings in SEC EDGAR's recent list, going back to Jul 15, 2015. Its latest annual report, Form 10-K, was filed on Aug 31, 2026 for the period ended May 31, 2026. The latest quarterly report (Form 10-Q) was filed on Oct 14, 2026, covering the quarter ended Aug 31, 2026. The most recent current report (Form 8-K) was filed on Oct 19, 2026 (officer or director change, regulation fd disclosure). The company's fiscal year ends on May 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFA14A | Additional proxy material | Oct 19, 2026 | — |
| DEF 14A | Proxy statement | Sep 28, 2026 | Sep 28, 2026 |
| DEFA14A | Additional proxy material | Nov 3, 2025 | — |
| DEFA14A | Additional proxy material | Sep 30, 2025 | — |
| DEF 14A | Proxy statement | Sep 29, 2025 | Nov 21, 2025 |
| PRE 14A | Preliminary proxy statement | Sep 19, 2025 | Nov 21, 2025 |
| DEF 14A | Proxy statement | Oct 11, 2024 | Nov 22, 2024 |
| DEFA14A | Additional proxy material | Nov 6, 2023 | — |
| DEFA14A | Additional proxy material | Oct 10, 2023 | — |
| DEFA14A | Additional proxy material | Sep 27, 2023 | — |
| DEF 14A | Proxy statement | Sep 25, 2023 | Nov 9, 2023 |
| PRE 14A | Preliminary proxy statement | Sep 15, 2023 | Nov 9, 2023 |
| DEFA14A | Additional proxy material | Dec 7, 2022 | — |
| DEFA14A | Additional proxy material | Dec 7, 2022 | — |
| DEFA14A | Additional proxy material | Nov 25, 2022 | — |
| DEF 14A | Proxy statement | Oct 26, 2022 | Dec 9, 2022 |
| DEF 14A | Proxy statement | Jul 22, 2022 | Aug 31, 2022 |
| PRE 14A | Preliminary proxy statement | Jul 8, 2022 | Aug 31, 2022 |
| DEFA14A | Additional proxy material | Nov 17, 2021 | — |
| DEFA14A | Additional proxy material | Oct 28, 2021 | — |
| DEFA14A | Additional proxy material | Oct 27, 2021 | — |
| DEFA14A | Additional proxy material | Oct 21, 2021 | — |
| DEFA14A | Additional proxy material | Oct 20, 2021 | — |
| DEFA14A | Additional proxy material | Oct 18, 2021 | — |
| DEFA14A | Additional proxy material | Oct 14, 2021 | — |
| DEFA14A | Additional proxy material | Oct 14, 2021 | — |
| DEFA14A | Additional proxy material | Sep 29, 2021 | — |
| DEFA14A | Additional proxy material | Sep 22, 2021 | — |
| DEFA14A | Additional proxy material | Sep 21, 2021 | — |
| DEFA14A | Additional proxy material | Sep 20, 2021 | — |
| DEFA14A | Additional proxy material | Sep 10, 2021 | — |
| DEFA14A | Additional proxy material | Sep 3, 2021 | — |
| DEFA14A | Additional proxy material | Aug 25, 2021 | — |
| DEFA14A | Additional proxy material | Aug 19, 2021 | — |
| DEFA14A | Additional proxy material | Aug 16, 2021 | — |
| DEFA14A | Additional proxy material | Aug 10, 2021 | — |
| DEFA14A | Additional proxy material | Aug 5, 2021 | — |
| DEFA14A | Additional proxy material | Aug 2, 2021 | — |
| DEFA14A | Additional proxy material | Jul 30, 2021 | — |
| DEF 14A | Proxy statement | Sep 1, 2020 | Sep 30, 2020 |
| DEFA14A | Additional proxy material | Jul 8, 2020 | — |
| DEF 14A | Proxy statement | Jun 22, 2020 | Jul 22, 2020 |
| PRE 14A | Preliminary proxy statement | Jun 8, 2020 | Jul 22, 2020 |
| DEF 14A | Proxy statement | Aug 21, 2019 | Sep 12, 2019 |
| DEF 14A | Proxy statement | Apr 22, 2019 | May 22, 2019 |
| PRE 14A | Preliminary proxy statement | Apr 10, 2019 | May 22, 2019 |
| DEF 14A | Proxy statement | Oct 15, 2018 | Nov 8, 2018 |
| PRE 14A | Preliminary proxy statement | Sep 7, 2018 | Oct 17, 2018 |
| DEFA14A | Additional proxy material | May 22, 2018 | — |
| DEF 14A | Proxy statement | May 8, 2018 | Jun 7, 2018 |
| PRE 14A | Preliminary proxy statement | Apr 26, 2018 | Jun 5, 2018 |
| DEF 14A | Proxy statement | Oct 2, 2017 | Nov 1, 2017 |
| PRE 14A | Preliminary proxy statement | Sep 20, 2017 | Nov 1, 2017 |
| DEF 14A | Proxy statement | Jul 24, 2017 | Aug 24, 2017 |
| PRE 14A | Preliminary proxy statement | Jul 10, 2017 | Aug 24, 2017 |
| DEF 14A | Proxy statement | Jul 20, 2016 | Aug 24, 2016 |
| PRE 14A | Preliminary proxy statement | Jul 8, 2016 | Aug 24, 2016 |
| DEF 14A | Proxy statement | Feb 18, 2016 | Mar 18, 2016 |
| PRE 14A | Preliminary proxy statement | Feb 8, 2016 | Mar 18, 2016 |
| DEF 14A | Proxy statement | Jul 17, 2015 | Aug 27, 2015 |
Showing 60 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- CYDY (OTC)
- Fiscal year ends
- May 31
- Incorporated in
- DE
- Headquarters
- Vancouver, WA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1175680
- Former names
- CYTODYN INC (until Apr 13, 2016); REXRAY CORP (until Nov 12, 2003)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.